BioCentury
ARTICLE | Finance

Nailing down an IPO

Anacor Pharma aims to reach Phase III data with IPO money.

November 8, 2010 8:00 AM UTC

Anacor Pharmaceuticals Inc. started on the road and set its range last week, hoping to sell 4.7 million shares at $16-$18. The IPO is slated for the week of Nov. 15. That puts at least four U.S. biotechs on the road selling IPOs.

A $17 price would raise $80 million and value the company at $294.3 million. In September, Anacor refiled to raise up to $86.3 million. In 2008, it withdrew an IPO for up to $57.5 million, citing market conditions...